# BPC-157 TB-500: The Two-Peptide Research Blend, Documented > BPC-157 TB-500 is a research-community pairing of two distinct synthetic peptides studied for tissue repair. A gallery of the published record, study by study, with the FDA 503A and WADA status surfaced first. Not one molecule but two: a cytoprotective pentadecapeptide paired with an actin-binding heptapeptide. Every finding is constituent-level and cited; the combination itself has no controlled trial, and we say so first. ## What the BPC-157 TB-500 record is BPC-157 TB-500 is a research-community name for a two-peptide pairing: BPC-157 (Body Protection Compound 157), a synthetic 15-amino-acid pentadecapeptide, set alongside TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) drawn from the actin-binding region of the protein Thymosin Beta-4. It is not a single chemical entity. It has no combined molecular weight, no CAS number, and no shared structure — the figures that exist describe its two constituents separately. The pairing is discussed as a tissue-repair "stack." The evidence behind it is a collection, not a single dataset: a transected-Achilles-tendon result here, a VEGFR2 angiogenesis finding there, an actin-sequestration crystal structure, a full-length-Thymosin-Beta-4 human safety study, a BPC-157 pharmacokinetic profile. This site sets that record out the way a gallery sets out specimens — one tile per study, each tagged with which leg of the blend it belongs to and what its evidence status actually is. The honest headline sits at the top of the wall. There is no controlled clinical trial of the BPC-157 TB-500 combination for any indication, and no peer-reviewed combination study defining a synergy ratio, dose, or endpoint [9][10]. Everything below is constituent-level. We surface that before the findings, not after them — and the practical reading on [BPC-157 TB-500 dosage](/dosing-protocol), on [why BPC-157 is paired with TB-500](/research), and on [Wolverine legal status and FDA 503A category](/legal-status) all carry the same caveat into their own pages. ## BPC-157 and TB-500: the two peptides in the blend BPC-157 and TB-500 are different in size, origin, and mechanism, and the pairing leans on that difference. BPC-157 is the cytoprotective and angiogenic leg. It is a 15-mer, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight approximately 1419.5 Da, derived from a partial sequence of a protein found in human gastric juice. In animal models it up-regulates VEGFR2 and signals through the VEGFR2-Akt-eNOS pathway, and it accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1][2]. TB-500 is the cytoskeletal and cell-migration leg. It is a 7-mer, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, molecular weight approximately 889 Da, corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4. The LKKTETQ helix binds monomeric G-actin one-to-one, regulating the cytoskeletal dynamics that drive cell migration [3]. One caveat travels with this leg everywhere on the site: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the heptapeptide [4][8]. ## The 'Wolverine' stack terminology "Wolverine" is community shorthand for the BPC-157 TB-500 stack — a name borrowed from the regenerative theme, not a registered product or a defined formulation. Commercial vials are commonly labeled with a combined per-vial mass, for example 10 mg BPC-157 plus 10 mg TB-500, but no standardized composition or ratio is clinically validated, and unregulated material has unverified identity and purity. The stack framing matters for how the evidence reads. Calling two peptides a "stack" does not produce a combined dataset; it produces two separate literatures discussed together. The synergy idea — that the two add up to more than the sum — is a theoretical extrapolation from each peptide's independently characterized mechanism, covered in full on the page about [the synergy claim and the evidence gap](/research). ## BPC 157 TB 500 (spacing and naming variants) BPC 157 TB 500, written without hyphens, is the same pairing as BPC-157 TB-500 — a spacing variant common in search and forum text. Other names for the same construct include the BPC-157 / TB-500 blend, the BPC-157 + TB-500 stack, the "Wolverine" peptide stack, and BPC157 TB500. The constituent identifiers stay fixed across every spelling: BPC-157 carries CAS 137525-51-0 and PubChem CID 108101; the TB-500 fragment is the acetylated Thymosin Beta-4 17-23 sequence; full-length Thymosin Beta-4 is UniProt P62328. ## Read the gallery by question What is the Wolverine peptide blend? A research-community name for a two-peptide pairing of BPC-157 with TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and its combination effect in humans is unproven [9]. What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide acting as the cytoprotective and angiogenic component; TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4, acting as the cytoskeletal and cell-migration component [1][3]. What is the difference between BPC-157 and TB-500? BPC-157 is a 15-mer gastric-juice-derived peptide acting locally via VEGFR2 and eNOS; TB-500 is a 7-mer fragment of Thymosin Beta-4 acting via G-actin sequestration [2][3]. Different size, origin, and mechanism, paired for complementary effects. The full reference list is indexed on the [references](/references) page. --- A dark-gallery digest of the BPC-157 and TB-500 record — every study hung as a cited specimen, the access status read first, and no clinic, vendor, or prescription behind the glass.